Canadian Cannabis Stocks

Q&A with CEO of CannaRoyalty (CNNRF), (CSE:CRZ), Marc Lustig

//
Comment0
CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. Our focus is building and supporting a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of holdings via royalty agreements, equity interests, secured convertible debt, licensing agreements and its own branded portfolio. Mr. Lustig holds MSc and MBA degrees from McGill University. He began his professional career in the pharmaceutical industry at Merck & Co. In 2000, he started his capital markets career in institutional equity research in the Life Sciences sector at Orion Securities. For the next 14 years, Mr. Lustig worked as a senior producer at GMP Securities L.P. and as Head of Capital Markets at Dundee Capital Markets before becoming Principal at KES 7 Capital. Mr. Lustig founded Cannabis Royalties & Holdings Corp. in early 2015. Cautionary Note on Forward-Looking Statements Certain statements contained in this interview may be “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov ). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Thank you Marc, for taking time to participate in this Q&A. MR: There’s a myriad of cannabis stocks for investors to choose from, many of which are focused solely on growing and selling cannabis. How is CannaRoyalty’s business model different, and why have you chosen this model? ML: I don’t care what anyone says, growing cannabis is an agricultural commodity. And while everyone claims to have a “proprietary process” and be the “greatest grower” its still a commodity which means lowest cost per unit at a...
Read More →

INTRODUCTION – CANADIAN CANNABIS MARKET

//
Comment0
Investment Overview: It is an exciting time to be in the cannabis business. What’s going on in Canada is as exciting as what is happening the United States. In fact, most of the volume and money is flowing into the Canadian Green Rush. We welcome you to cannabisstockpicks where we focus on US and Canadian Cannabis Stocks. We welcome you to join us in exploring the most exciting opportunity since prohibition! We stress that, at this time, our company reviews are informational and not recommendations to purchase shares. When the fundamentals, technicals, news flow, and overall market give us a “buy signal”, we will provide specific buy recommendations then. Market Dynamics: Recreational Use. Canada’s government said on 12/13 it would study a federal task force’s recommendation that Canadians over 18 years old be allowed to buy marijuana for recreational purposes and would announce new laws in the Spring for legalizing pot. Prime Minister Trudeau has long promised to legalize recreational pot use and sales. Limited Licenses. Canada’s stance to limit the number of licenses for growers, distributors, etc., is of special interest to investors. That practice by the state opens up the possibility to create large, robust companies. And venture firms are happy to back those. The three leading Canadian cannabis companies — Aurora Cannabis, Aphria and Canopy Growth — have each raised nearly $30 million from investors. Investors could win big by picking the winning company that is protected from future competition through a license. International Opportunities. Globally, $150 billion was spent last year on marijuana in 2015, according to studies. Investors myopically focused on the just the United States while miss so much of the opportunity. The Great White North (aka Canada) was the first country to legalize medical marijuana on a federal level in 2001. Others around the world are looking to Canada and likely to follow its lead. Getting to know the Canada Cannabis market is a smart bet for investors. Canopy Growth Corp Canopy Growth Corp is based in Ontario. Canopy, formerly Tweed Marijuana Inc, is a diversified cannabis company. The Company, through its subsidiaries Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) and Tweed Farms Inc. (Tweed Farms), is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan....
Read More →

CannaRoyalty Corp. (OTC: CNNRF)

//
Comment0
By Gary Anderson – CannaRoyalty Corp. (CNNRF): Unique Business Model a Big Winner in Cannabis Space CannaRoyalty Corp. (CNNRF) and (CSE:CRZ), has a unique business model in the cannabis space that minimizes risk and maximizes reward CannaRoyalty holds 22 strategic, diverse cannabis assets throughout North America Just one $850,000 investment in one cannabis asset now valued at $7.1M Exceptionally strong management team and board of directors positioning company to capitalize on high-growth cannabis market This article will provide an overview of CannaRoyalty’s intriguing business model and distinguished management team, and identify the company’s diversified cannabis assets. A future article will take closer look at the CannaRoyalty assets and determine a valuation range for the company. CannaRoyalty Corp. at a glance: Tickers: (OTC:CNNRF), (CSE:CRZ) Shares outstanding: 42.5 million Closing price 3/31/17: $2.21 USD Market cap: $94 million Float: 31.4 million Insider ownership: 20% Web site: CannaRoyalty.com CannaRoyalty Corp. is a fully integrated, active investor and operator in the legal cannabis sector. The Company’s focus is to build and support a diversified portfolio of growth-ready assets in key segments of the cannabis sector, including research, consumer brands, devices and intellectual property. CannaRoyalty’s management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of holdings via royalty agreements, equity interests, secured convertible debt and licensing agreements. CannaRoyalty was formed in late 2014 and began trading publicly on December 8th of 2016. CannaRoyalty’s $850,000 Investment in Resolve Digital Health Grows to $7.1M Asset CannaRoyalty’s December 2015 $850,000 investment in Resolve Digital Health is a perfect example of an early...
Read More →

Q&A with John Stewart, CEO of Emblem Pharmaceutical Division at Emblem Corp (EMC.V) (EMMBF)

//
Comment1
Cautionary Note on Forward-Looking Statements Certain statements contained in this interview may be “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov ). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Emblem Corp. (web site) is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marijuana. Emblem carries out its principal activities producing marijuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. CannabisStockPicks: Congratulations on the successful public launch of Emblem Corp (TSX-V: EMC.V) and (U.S. OTC: EMMBF). Can you give investors an overview of your past experience with Purdue Pharma, and how it...
Read More →

Aphria Inc. (OTCQB: APHQF)

//
Comment0
By Jon Slotnick –  We first brought your attention to the shares of Aphria, Inc.—one of the leading companies in Canada’s rapidly growing cannabis industry—two weeks ago, highlighting Aphria’s growing bottom line, impressive cash reserves, and an aggressive expansion strategy. A series of solid quarterly reports had already underscored the company’s steady growth, which attracted about $40 million in investor capital over the past year. As we noted in our initial story about Aphria, the company had recently reported blowout Q1 results, released this past October. During that first quarter period the company banked sales of $4.37 million, along with a profit of $895,000. That compared year-over-year to Q116 sales of $950,000, and a loss of $476,000. Since we published that story less than two weeks ago, the company unleashed yet another positive quarterly report earlier this month, which should bode well for long-term holders of APHQF stocks. For fiscal Q216, Aphria weighed in with $5.2 million in sales, a 19% jump sequentially from Q116. The company also continued to report strong EBITDA growth—which jumped 13% to $1.2 million, compared to $4,000 total in the comparable 2015 period. The impressive EBITDA growth was due, in part, to the company’s ability to produce at a lower cost as it scales up its operations. The sales increase was mainly a result of increased average selling price per gram. Net income for the three months ended November 30, 2016 was $945,678 or $0.01 per share as opposed to a net loss of $431,098 or $0.01...
Read More →

Aphria Inc. (OTCQB: APHQF, TSX: APH)

//
Comment1
By Jon Slotnick –  When Health Canada, Canada’s federal health authority that governs cannabis regulation, first licensed Aphria Inc. to produce medical marijuana in November, 2014, it appeared that the company might be late to the dance. By that time 13 other companies had been issued grow licenses, so the field was already quite crowded. Over the past two years, however, Aphria has quickly emerged as one of the heaviest hitters in Canada’s rapidly growing cannabis industry. One month after receiving its license, in December, 2014, 52 million Aphria shares began trading on Toronto’s TSX venture exchange under the symbol APH. At the time, the company immediately caught investors’ attention, in part due to the impressive pedigree of its management team, headed by Vic Neufeld, who previously served as CEO of Jamieson Laboratories, a major vitamin manufacturer. As it turns out, Aphria was anything but late to Canada’s burgeoning medical cannabis trade. In fact, prior to receiving their full license, the company had been operating on a partial Health Canada permit which allowed them to grow and inventory cannabis. That job fell to Neufeld’s partners in the company, greenhouse operators Cole Cacciavillani and John Cervini, who were a perfect pit for Aphria—already growing and distributing flowers and vegetables for large Canadian retail chains. Blowout Q1 Results             CEO Vic Neufeld Flash forward two years later to October, 2016, when the company reported Q117 results, and you’re looking at one of the two biggest players in Canada’s bullish public cannabis sector. For...
Read More →

Emblem Corp. (TSX-V: EMC)

//
Comment0
Canadian marijuana stocks have been on fire recently, and one of the most highly anticipated stocks to begin trading in the space is Emblem Corp. Pre-trading interest from investors in Emblem Corp. has been extremely high with shares oversubscribed Emblem shares begin trading this week on the TSX Venture Exchange (TSX-V: EMC), with an OTC listing in the U.S. pending U.S.-based investors can buy shares of Emblem on the TSX Venture Exchange with major online brokers. Buying shares prior to the initiation of trading on the U.S. OTC market in the coming weeks could prove to be extremely profitable, as a large increase in demand for a float of just 6 million shares will be felt when trading begins on the OTC market in the U.S. The Emblem Pharmaceutical division is led by John H. Stewart, who launched 11 new products, including OxyContin while he was President and CEO of Purdue Pharma, one of the largest privately held pharmaceutical companies in the world Emblem Corp. (TSX-V: EMC) (web site) is a licensed producer of Medical Marijuana in Canada, led by a team of former HealthCare & Pharma Executives who have built & run multi-billion dollar companies and have invested heavily into the company themselves.   Shares issued and outstanding: 37.3 million Approximate float: 6 million Estimated opening share price range: $1.15-$1.50 Booming Medical Marijuana Market While many sources confirm the hyper-growth of Canada’s medical marijuana industry, the most telling is from the government’s own Health Canada site that reports over 220% growth in registered clients in the Medical Marijuana Program between September of last year to...
Read More →

Canopy Growth Corp. (CVE: CGC)

//
Comment0
Canopy Growth Corp. (CVE: CGC), formerly Tweed Marijuana Inc, is a diversified cannabis company. The Company, through its subsidiaries Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) and Tweed Farms Inc. (Tweed Farms), is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan. Tweed is a licensed producer of medical marijuana. Tweed’s commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed’s built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan’s over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms. It should be noted that Tweed has entered into a joint venture with Snoop Dog.